Currently, there is a clinical trial aimed at investigating GAS5 expression elevation in peripheral blood mononuclear cells (PBMCs), which has been associated with steroid resistance in idiopathic nephrotic syndrome (INS), particularly in steroid-resistant nephrotic syndrome (SRNS), where GAS5 may impede GR activity and contribute to glucocorticoid insensitivity (clinicaltrials.gov; ID: NCT06325137). Here, GAS5 is linked to idiopathic nephrotic syndrome.